Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-label Study Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT07565389 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT07565389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07565389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-label Study Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
Lead sponsor
National University Hospital, Singapore
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
May 31, 2031
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma (npc)